Heptares creates new medicines targeting previously undruggable or challenging GPCRs, a superfamily of receptors linked to many diseases. We are pioneering a structure-based drug design approach to GPCRs, leveraging proprietary technologies for protein stabilisation, structure determination, and fragment-based discovery. Our partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune. Our objective is to build a broad pipeline of novel medicines to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression, chronic insomnia, addiction, migraine and diabetes.

Heptares is focused on the discovery of agents targeting GPCRs, and we have already had experience of projects where the dissociation rates of ligands are important for their progression. Using our proprietary StaR technology Heptares can generate GPCRs stabilised in a specific conformation which are suitable for biophysical analyses of ligand binding, including kinetics. K4DD gives us the opportunity to characterize the kinetic properties of sets of ligands for a number of receptors, and work with other experts in drug discovery to understand the physiological significance of these data.